Send to

Choose Destination
Curr Med Chem. 2019 Nov 8. doi: 10.2174/0929867326666191108160643. [Epub ahead of print]

Towards Better Drug Repositioning: Targeted Immunoinflammatory Therapy for Diabetic Nephropathy.

Author information

Department of Nephrology, 2ndXiangya Hospital, Central South University, Changsha, Hunan. China.
Department of Nephrology, 3rdXiangya Hospital, Central South University, Changsha, Hunan. China.


Diabetic nephropathy (DN) is one of the most common and important microvascular complications of diabetes mellitus (DM). The main clinical features of DN are proteinuria and a progressive decline in renal function , which are associated with structural and functional changes in the kidney. The pathogenesis of DN is multifactorial, including genetic, metabolic and haemodynamic factors, which can trigger a sequence of events. Controlling metabolic risks such as hyperglycaemia, hypertension and dyslipidaemia is not enough to slow the progression of DN. Recent studies have emphasized immunoinflammation as a critical pathogenic factor in the progression of DN. Therefore, targeting inflammation is considered a potential and novel treatment strategy for DN. In this review, we will briefly introduce the inflammatory process of DN and discuss the anti-inflammatory effects of antidiabetic drugs when treating DN.


Diabetic nephropathy; glucagon-like peptide-1 analogue; immunoinflammatory; metformin; phosphodiesterase inhibitors; spironolactone; stains; vitamin D

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center